STOCK TITAN

TScan Therapeutics, Inc. - $TCRX STOCK NEWS

Welcome to our dedicated page for TScan Therapeutics news (Ticker: $TCRX), a resource for investors and traders seeking the latest updates and insights on TScan Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TScan Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TScan Therapeutics's position in the market.

Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) is set to present two abstracts at the 2024 American Society of Clinical Oncology Annual Meeting. The presentations focus on T cell receptor-engineered T cell therapies for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
conferences
-
Rhea-AI Summary
TScan Therapeutics announced the partial exercise of underwriters' option to purchase additional shares, resulting in gross proceeds of approximately $167.8 million from a total of 4,958,068 shares sold at $7.13 per share. The underwriters of the public offering closed on April 19, 2024, have partially exercised their over-allotment option, leading to the purchase of 2,485,487 additional shares of voting common stock. Morgan Stanley and TD Cowen served as joint book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
-
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) will present at the ASGCT 27th Annual Meeting with one oral and four poster presentations focusing on TCR-engineered T cell therapies for cancer treatment. The company aims to showcase advancements in tumor-reactive TCRs and T cell therapies for various cancers, emphasizing non-clinical and clinical trial progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
conferences
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) closed an underwritten public offering of 2,472,581 shares of its common stock and pre-funded warrants for approximately $150.1 million. The company granted underwriters an option to purchase additional shares. The proceeds will be used for general corporate purposes, extending the company's cash runway into the fourth quarter of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
-
Rhea-AI Summary
TScan Therapeutics, a biopharmaceutical company, announced the pricing of an upsized $150 million public offering. The offering includes shares of its voting common stock and pre-funded warrants, with gross proceeds expected to be approximately $150.1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
-
Rhea-AI Summary
TScan Therapeutics, a biopharmaceutical company, is launching a $125 million public offering for the development of TCR-T cell therapies for cancer treatment. The offering includes voting common stock and pre-funded warrants, with underwriters having an option to purchase additional shares. The proceeds will be used for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) provides an update on its solid tumor and heme malignancies clinical programs. Over 40 solid tumor patients completed biomarker testing, with 60% qualifying for TCR-T therapy. All heme program patients remain relapse-free. The company plans to dose the first three solid tumor patients in early May 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
none
-
Rhea-AI Summary
TScan Therapeutics appoints Dr. Chrystal Louis as Chief Medical Officer, bringing extensive experience in hematology and oncology drug development. Dr. Louis will lead the clinical and commercial development of TCR-engineered T cell therapies for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
management
-
Rhea-AI Summary
TScan Therapeutics, Inc. (TCRX) will present at the 23rd Annual Needham Virtual Healthcare Conference to discuss their TCR-engineered T cell therapies for cancer treatment. The presentation will be available via webcast on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.11%
Tags
conferences
Rhea-AI Summary
TScan Therapeutics, Inc. (TCRX) reports updated data from Phase 1 study showing positive outcomes for heme malignancies treatment. They also announced the clearance of two additional INDs for their Solid Tumor Program. Financially, the company has strong cash reserves to fund operations into 2026 and has seen revenue growth in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
TScan Therapeutics, Inc.

Nasdaq:TCRX

TCRX Rankings

TCRX Stock Data

458.32M
21.10M
0.89%
83.08%
0.46%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
WALTHAM

About TCRX

harnessing novel t cell systems to extend the promise of immunotherapy